MeSH term
Frequency | Condition_Probility | Antineoplastic Agents, Alkylating/pharmacology | 2 | 7.0 |
*DNA Helicases | 6 | 2.0 |
DNA Repair/*physiology | 7 | 6.0 |
DNA-Binding Proteins/*metabolism | 11 | 0.0 |
Drug Resistance, Neoplasm/*genetics/physiology | 2 | 50.0 |
*Endonucleases | 12 | 12.0 |
Female | 26 | 0.0 |
Humans | 116 | 0.0 |
Male | 22 | 0.0 |
Neoplasms/*drug therapy/metabolism | 2 | 8.0 |
Proteins/*metabolism | 4 | 0.0 |
Research Support, Non-U.S. Gov't | 74 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 49 | 0.0 |
*Transcription Factors | 6 | 0.0 |
Tumor Cells, Cultured | 7 | 0.0 |
Base Sequence | 19 | 0.0 |
Binding Sites | 10 | 0.0 |
*DNA Damage | 17 | 2.0 |
DNA Repair | 23 | 3.0 |
Dose-Response Relationship, Drug | 7 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 3 | 0.0 |
Introns | 2 | 0.0 |
Molecular Sequence Data | 13 | 0.0 |
Mutagenesis, Site-Directed | 3 | 0.0 |
Protein Binding | 21 | 0.0 |
Recombination, Genetic | 3 | 0.0 |
Ultraviolet Rays | 18 | 2.0 |
Cells, Cultured | 8 | 0.0 |
Comparative Study | 10 | 0.0 |
*DNA Repair | 39 | 5.0 |
Kinetics | 13 | 0.0 |
Models, Biological | 2 | 0.0 |
Pyrimidine Dimers/metabolism | 3 | 16.0 |
Amino Acid Sequence | 6 | 0.0 |
Animals | 43 | 0.0 |
DNA-Binding Proteins/chemistry/genetics/*metabolism | 4 | 2.0 |
Flow Cytometry | 3 | 0.0 |
Mice | 20 | 0.0 |
Sequence Alignment | 2 | 0.0 |
Cisplatin/pharmacology | 6 | 3.0 |
DNA Replication | 4 | 1.0 |
DNA-Binding Proteins/genetics/*metabolism | 3 | 0.0 |
Substrate Specificity | 3 | 0.0 |
Xeroderma Pigmentosum/genetics | 7 | 24.0 |
DNA Adducts/metabolism | 2 | 5.0 |
DNA Damage | 17 | 2.0 |
*DNA Replication | 2 | 0.0 |
DNA, Single-Stranded/metabolism | 5 | 7.0 |
DNA-Binding Proteins/chemistry/*metabolism | 4 | 2.0 |
Fluorescence Polarization | 2 | 3.0 |
Fluorescent Dyes/metabolism | 2 | 2.0 |
Recombinant Proteins/metabolism | 2 | 0.0 |
Spectrometry, Fluorescence | 3 | 0.0 |
Xenopus laevis | 2 | 0.0 |
Xeroderma Pigmentosum | 5 | 33.0 |
Apyrase/metabolism | 2 | 28.0 |
Indomethacin/pharmacology | 2 | 0.0 |
Isoenzymes/genetics | 2 | 0.0 |
Prostaglandin-Endoperoxide Synthase/genetics | 2 | 8.0 |
RNA, Messenger/metabolism | 5 | 0.0 |
*Ultraviolet Rays | 8 | 3.0 |
DNA/metabolism | 4 | 0.0 |
Endonucleases/*metabolism | 2 | 10.0 |
In Vitro | 3 | 0.0 |
Cell Line, Transformed | 5 | 0.0 |
Transfection | 5 | 0.0 |
Animal Testing Alternatives | 2 | 28.0 |
Carcinogenicity Tests/*methods | 2 | 33.0 |
Carcinogens/*toxicity | 3 | 2.0 |
DNA Repair/genetics | 3 | 1.0 |
DNA-Binding Proteins/deficiency/*genetics | 2 | 14.0 |
Disease Models, Animal | 4 | 0.0 |
*Genes, p53 | 4 | 0.0 |
Mice, Knockout | 9 | 0.0 |
Mice, Transgenic | 6 | 0.0 |
Mutagens/*toxicity | 6 | 5.0 |
RNA-Binding Proteins/*genetics | 5 | 4.0 |
DNA Repair/*genetics | 15 | 4.0 |
*Disease Models, Animal | 4 | 1.0 |
Genotype | 4 | 0.0 |
Mutagens/toxicity | 3 | 8.0 |
Skin Neoplasms/chemically induced/*genetics | 2 | 66.0 |
Xeroderma Pigmentosum/*genetics | 16 | 28.0 |
Cockayne Syndrome/genetics | 3 | 21.0 |
DNA, Neoplasm/analysis | 2 | 0.0 |
DNA-Binding Proteins/genetics | 7 | 0.0 |
*Loss of Heterozygosity | 3 | 0.0 |
Lung Neoplasms/etiology/*genetics | 2 | 7.0 |
Microsatellite Repeats | 3 | 0.0 |
Hamsters | 8 | 0.0 |
Rats | 2 | 0.0 |
Aged | 5 | 0.0 |
Case-Control Studies | 4 | 0.0 |
DNA Helicases/genetics | 2 | 9.0 |
Middle Aged | 6 | 0.0 |
Odds Ratio | 2 | 0.0 |
Polymorphism, Genetic | 3 | 0.0 |
Risk Factors | 4 | 0.0 |
*Variation (Genetics) | 2 | 0.0 |
Chromatography, High Pressure Liquid | 3 | 0.0 |
Circular Dichroism | 3 | 0.0 |
Protein Conformation | 5 | 0.0 |
Protein Structure, Tertiary | 5 | 0.0 |
Recombinant Fusion Proteins/metabolism | 3 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 10 | 0.0 |
Surface Plasmon Resonance | 3 | 1.0 |
Ultraviolet Rays/adverse effects | 5 | 7.0 |
Xeroderma Pigmentosum/genetics/metabolism | 5 | 62.0 |
Carcinoma, Squamous Cell/etiology/*genetics | 2 | 25.0 |
DNA-Binding Proteins/*genetics | 13 | 0.0 |
DNA Primers | 4 | 0.0 |
Immunohistochemistry | 5 | 0.0 |
RNA, Messenger/genetics | 5 | 0.0 |
Staining and Labeling | 2 | 0.0 |
Base Pair Mismatch | 3 | 1.0 |
Escherichia coli | 2 | 0.0 |
Nucleic Acid Conformation | 3 | 0.0 |
Oligodeoxyribonucleotides/chemistry/metabolism | 2 | 6.0 |
Escherichia coli/genetics | 6 | 1.0 |
Genetic Predisposition to Disease | 5 | 0.0 |
Mutation | 9 | 0.0 |
Binding, Competitive | 2 | 0.0 |
DNA/*metabolism | 3 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 7 | 0.0 |
Models, Molecular | 4 | 0.0 |
Protein Structure, Secondary | 4 | 0.0 |
Time Factors | 6 | 0.0 |
2-Acetylaminofluorene/toxicity | 3 | 37.0 |
Lac Operon | 3 | 2.0 |
*Mutation | 2 | 0.0 |
Adolescent | 9 | 0.0 |
Adult | 11 | 0.0 |
Child | 6 | 0.0 |
Proteins/metabolism | 2 | 0.0 |
Cell Extracts | 2 | 1.0 |
DNA-Binding Proteins/metabolism | 5 | 0.0 |
Fibroblasts | 2 | 0.0 |
Hela Cells | 12 | 0.0 |
*Nucleic Acid Conformation | 2 | 2.0 |
Transcription, Genetic/*genetics | 2 | 1.0 |
Cell-Free System | 3 | 1.0 |
DNA-Binding Proteins/*genetics/metabolism | 2 | 0.0 |
*Saccharomyces cerevisiae Proteins | 3 | 0.0 |
*Transcription Factors, TFII | 5 | 4.0 |
Xeroderma Pigmentosum/metabolism | 4 | 44.0 |
Heterozygote | 2 | 0.0 |
Mice, Inbred C57BL | 4 | 0.0 |
Antineoplastic Agents/*pharmacology | 2 | 0.0 |
Cisplatin/*pharmacology | 3 | 2.0 |
Tumor Cells, Cultured/drug effects | 2 | 0.0 |
Macromolecular Substances | 4 | 0.0 |
Gene Expression | 4 | 0.0 |
Platinum/pharmacology | 2 | 100.0 |
Transcription, Genetic | 2 | 0.0 |
Protein Biosynthesis | 2 | 0.0 |
Proteins/genetics | 3 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 3 | 0.0 |
Binding Sites/genetics | 3 | 0.0 |
*DNA-Binding Proteins | 3 | 0.0 |
Hypoxanthine Phosphoribosyltransferase/genetics | 2 | 2.0 |
Models, Genetic | 3 | 0.0 |
Cell Line | 16 | 0.0 |
Genetic Vectors | 3 | 0.0 |
Oligodeoxyribonucleotides/chemistry/*metabolism | 2 | 40.0 |
DNA/chemistry/*metabolism | 2 | 3.0 |
Magnetic Resonance Spectroscopy | 3 | 0.0 |
Blotting, Southern | 2 | 0.0 |
DNA Damage/drug effects | 3 | 6.0 |
Loss of Heterozygosity/*genetics | 2 | 2.0 |
Simian virus 40/genetics | 3 | 2.0 |
DNA Replication/genetics | 2 | 3.0 |
Edema/etiology | 2 | 14.0 |
Aged, 80 and over | 2 | 0.0 |
Glutathione Transferase/genetics | 2 | 0.0 |
Retrospective Studies | 2 | 0.0 |
Blotting, Western | 4 | 0.0 |
Child, Preschool | 2 | 0.0 |
*Point Mutation | 2 | 0.0 |
Radiation Tolerance/genetics | 2 | 4.0 |
Xeroderma Pigmentosum/*genetics/pathology | 2 | 28.0 |
DNA-Binding Proteins/*chemistry/metabolism | 2 | 2.0 |
Peptide Fragments/chemistry/metabolism | 2 | 1.0 |
CHO Cells | 4 | 0.0 |
Sequence Deletion | 3 | 0.0 |
Zinc Fingers | 2 | 0.0 |
Blotting, Northern | 2 | 0.0 |
Carcinoma, Squamous Cell/*genetics | 2 | 1.0 |
Dose-Response Relationship, Radiation | 5 | 1.0 |
Skin Neoplasms/*genetics | 4 | 3.0 |
Chromosomes, Human, Pair 9 | 3 | 1.0 |
Membrane Proteins/*genetics | 2 | 0.0 |
Polymorphism, Single-Stranded Conformational | 2 | 0.0 |
Mice, Mutant Strains | 3 | 0.0 |
Neoplasms, Radiation-Induced/*genetics | 2 | 7.0 |
Polymerase Chain Reaction | 5 | 0.0 |
*Polymorphism, Genetic | 3 | 0.0 |
Cell Division | 2 | 0.0 |
Gene Expression Regulation | 2 | 0.0 |
Chromosome Mapping | 3 | 0.0 |
*Chromosomes, Human, Pair 9 | 2 | 0.0 |
Cell Line, Tumor | 2 | 0.0 |
Proteins/chemistry/*metabolism | 2 | 2.0 |
Genetic Complementation Test | 6 | 1.0 |
Molecular Structure | 2 | 0.0 |
*Psoralens | 2 | 100.0 |
Polymorphism, Restriction Fragment Length | 2 | 0.0 |
Molecular Weight | 3 | 0.0 |
Precipitin Tests | 3 | 0.0 |
Biotransformation | 2 | 0.0 |
Cell Survival/drug effects | 2 | 0.0 |
Mutagenesis | 2 | 0.0 |
Fibroblasts/drug effects/metabolism | 2 | 1.0 |
Biological Markers | 2 | 0.0 |
Hela Cells/drug effects | 2 | 7.0 |
Plasmids | 3 | 0.0 |
DNA/*radiation effects | 2 | 7.0 |
Fibroblasts/radiation effects | 2 | 7.0 |
